Transcriptional regulation of the homeobox gene NKX3.1 by all-trans retinoic acid in prostate cancer cells

Journal of Cellular Biochemistry

Volumn 99, Issue 5, 2006, Pages 1409-1419

  Thomas, Marc A ^a   Hodgson, Myles C ^a   Loermans, Susan D ^a   Hooper, Joel ^a   Endersby, Raelene ^a   Bentel, Jacqueline M ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Gene regulation; NKX3.1; Prostate cancer; Retinoids

Indexed keywords

ANDROGEN; CYCLOHEXIMIDE; LUCIFERASE; MESSENGER RNA; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOL;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CARCINOGENESIS; CONTROLLED STUDY; DISEASE COURSE; DNA SEQUENCE; ENZYME ACTIVITY; GENE CONSTRUCT; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HOMEOBOX; HUMAN; HUMAN CELL; MOLECULAR CLONING; NKX3 1 GENE; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN INDUCTION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; RNA STABILITY; SEQUENTIAL ANALYSIS; TRANSCRIPTION REGULATION; UNTRANSLATED REGION; WESTERN BLOTTING;

3' UNTRANSLATED REGIONS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION; GENES, REPORTER; HOMEODOMAIN PROTEINS; HUMANS; MALE; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; RECEPTORS, RETINOIC ACID; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRETINOIN;

EID: 33751190311     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21020     Document Type: Article

References (61)

1. Abdulkadir SA, Magee JA, Peters TJ, Kaleem Z, Naughton CK, Humphrey PA, Milbrandt J. 2002. Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol Cell Biol 22:1495-1503.
2. Alfaro JM, Fraile B, Lobo MVT, Royuela M, Paniagua R, Arenas MI. 2003. Immunohistochemical detection of the retinoid X receptors α, β and γ in human prostate. J Androl 24:113-119.
3. Altucci L, Gronemeyer H. 2001. The promise of retinoids to fight against cancer. Nat Rev Cancer 1:181-193.
4. Asatiani E, Huang WX, Wang A, Rodriguez Ortner E, Cavalli LR, Haddad BR, Gelmann EP. 2005. Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer. Cancer Res 65:1164-1173.
5. Aslan G, Irer B, Tuna B, Yorukoglu K, Saatcioglu F, Celebi I. 2006. Analysis of NKX3.1 expression in prostate cancer tissues and correlation with clinicopathologic features. Pathol Res Pract 202:93-98.
6. Bastien J, Rochette-Egly C. 2004. Nuclear retinoid receptors and the transcription of retinoid-target genes. Gene 328:1-16.
7. Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, Kim M, Desai N, Young P, Norton CR, Gridley T, Cardiff RD, Cunha GR, Abate-Shen C, Shen MM. 1999. Roles for Nkx3.1 in prostate development and cancer. Genes Dev 13:966-977.
8. Bieberich CJ, Fujita K, He WW, Jay G. 1996. Prostate-specific and androgen-dependent expression of a novel homeobox gene. J Biol Chem 271:31779-31782.
9. Bigler J, Eisenman RN. 1995. Novel location and function of a thyroid hormone response element. Embo J 14:5710-5723.
10. Boone CW, Kelloff GJ, Malone WE. 1990. Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: A review. Cancer Res 50:2-9.
11. Bowen C, Bubendorf L, Voeller HJ, Slack R, Willi N, Sauter G, Gasser TC, Koivisto P, Lack EE, Kononen J, Kallioniemi OP, Gelmann EP. 2000. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res 60:6111-6115.
12. Butts BD, Tran NL, Briehl MM. 2004. Identification of a functional peroxisome proliferator activated receptor response element in the 3′ untranslated region of the human bcl-2 gene. Int J Oncol 24:1305-1310.
13. Chen H, Mutton LN, Prins GS, Bieberich CJ. 2005. Distinct regulatory elements mediate the dynamic expression pattern of Nkx3.1. Dev Dyn 234:961-973.
14. Chopra DP, Wilkoff LJ. 1977. Reversal by vitamin A analogues (retinoids) of hyperplasia induced by N-methyl-N′-nitro-N-nitrosoguanidine in mouse prostate organ cultures. J Natl Cancer Inst 58:923-930.
15. Culine S, Kramar A, Droz JP, Theodore C. 1999. Phase II study of all-trans retinoic acid administered intermittently for hormone refractory prostate cancer. J Urol 161:173-175.
16. Dahiya R, Boyle B, Park HD, Kurhanewicz J, Macdonald JM, Narayan P. 1994. 13-cis-retinoic acid-mediated growth inhibition of DU-145 human prostate cancer cells. Biochem Mol Biol Int 32:1-12.
17. de Vos S, Dawson MI, Holden S, Le T, Wang A, Cho SK, Chen DL, Koeffler HP. 1997. Effects of retinoid X receptor-selective ligands on proliferation of prostate cancer cells. Prostate 32:115-121.
18. Dohle GR, Smit M, Weber RF. 2003. Androgens and male fertility. World J Urol 21:341-345.
19. Emmert-Buck MR, Vocke CD, Pozzatti RO, Duray PH, Jennings SB, Florence CD, Zhuang Z, Bostwick DG, Liotta LA, Linehan WM. 1995. Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res 55:2959-2962.
20. Esquenet M, Swinnen JV, Heyns W, Verhoeven G. 1996. Control of LNCaP proliferation and differentiation: Actions and interactions of androgens, 1alpha,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate. Prostate 28:182-194.
21. Gary B, Azuero R, Mohanty GS, Bell WC, Eltoum IE, Abdulkadir SA. 2004. Interaction of Nkx3.1 and p27kip1 in prostate tumor initiation. Am J Pathol 164:1607-1614.
22. Goossens K, Deboel L, Swinnen JV, Roskams T, Manin M, Rombauts W, Verhoeven G. 2002. Both retinoids and androgens are required to maintain or promote functional differentiation in reaggregation cultures of human prostate epithelial cells. Prostate 53:34-49.
23. Gronberg H. 2003. Prostate cancer epidemiology. Lancet 361:859-864.
24. Grzybowska EA, Wilczynska A, Siedlecki JA. 2001. Regulatory functions of 3′UTRs. Biochem Biophys Res Commun 288:291-295.
25. Gyftopoulos K, Perimenis P, Sotiropoulou-Bonikou G, Sakellaropoulos G, Varakis I, Barbalias GA. 2000a. Immunohistochemical detection of retinoic acid receptor-alpha in prostate carcinoma: Correlation with proliferative activity and tumor grade. Int Urol Nephrol 32:263-269.
26. Gyftopoulos K, Sotiropoulou G, Varakis I, Barbaliaas GA. 2000b) Cellular distribution of retinoic acid receptor-alpha in benign hyperplastic and malignant human prostates: Comparison with androgen, estrogen and progesterone receptor status. Eur Urol 38:323-330.
27. Hayes RB, Bogdanovicz JF, Schroeder FH, De Bruijn A, Raatgever JW, Van der Maas PJ, Oishi K, Yoshida O. 1988. Serum retinol and prostate cancer. Cancer 62:2021-2026.
28. He WW, Sciavolino PJ, Wing J, Augustus M, Hudson P, Meissner PS, Curtis RT, Shell BK, Bostwick DG, Tindall DJ, Gelmann EP, Abate-Shen C, Carter KC. 1997. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 43:69-77.
29. Hsing AW, Chokkalingam AP. 2006. Prostate cancer epidemiology. Front Biosci 11:1388-1413.
30. Hyder SM, Nawaz Z, Chiappetta C, Stancel GM. 2000. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res 60:3183-3190.
31. Jansa P, Forejt J. 1996. A novel type of retinoic acid response element in the second intron of the mouse H2Kb gene is activated by the RAR/RXR heterodimer. Nucleic Acids Res 24:694-701.
32. Jarrard DF, Kinoshita H, Shi Y, Sandefur C, Hoff D, Meisner LF, Chang C, Herman JG, Isaacs WB, Nassif N. 1998. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res 58:5310-5314.
33. Jiang AL, Zhang JY, Young C, Hu XY, Wang YM, Liu ZF, Hao ML. 2004. Molecular cloning and characterization of human homeobox gene Nkx3.1 promoter. Acta Biochim Biophys Sin 37(11):773-778.
34. Kambe T, Tada-Kambe J, Kuge Y, Yamaguchi-Iwai Y, Nagao M, Sasaki R. 2000. Retinoic acid stimulates erythropoietin gene transcription in embryonal carcinoma cells through the direct repeat of a steroid/thyroid hormone receptor response element half-site in the hypoxia-response enhancer. Blood 96:3265-3271.
35. Kikugawa T, Tanji N, Miyazaki T, Yokoyama M. 2000) Immunohistochemical study of the receptors for retinoic acid in prostatic adenocarcinoma. Anticancer Res 20:3897-3902.
36. Kim MJ, Bhatia-Gaur R, Banach-Petrosky WA, Desai N, Wang Y, Hayward SW, Cunha GR, Cardiff RD, Shen MM, Abate-Shen C. 2002a. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res 62:2999-3004.
37. Kim MJ, Cardiff RD, Desai N, Banach-Petrosky WA, Parsons R, Shen MM, Abate-Shen C. 2002b. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci USA 99:2884-2889.
38. Kishimoto H, Hoshino S, Ohori M, Kontani K, Nishina H, Suzawa M, Kato S, Katada T. 1998. Molecular mechanism of human CD38 gene expression by retinoic acid. Identification of retinoic acid response element in the first intron. J Biol Chem 273:15429-15434.
39. Korkmaz KS, Korkmaz CG, Ragnhildstveit E, Kizildag S, Pretlow TG, Saatcioglu F. 2000. Full-length cDNA sequence and genomic organization of human NKX3A-Alternative forms and regulation by both androgens and estrogens. Gene 260:25-36.
40. Langston AW, Thompson JR, Gudas LJ. 1997. Retinoic acid-responsive enhancers located 3′ of the Hox A and Hox B homeobox gene clusters. Functional analysis. J Biol Chem 272:2167-2175.
41. Lasnitzki I, Goodman DS. 1974. Proceedings: Inhibition of the effects of methylcholanthrene by vitamin A and vitamin A analogues. Br J Cancer 29:94.
42. Lind GE, Skotheim RI, Fraga MF, Abeler VM, Henrique R, Saatcioglu F, Esteller M, Teixeira MR, Lothe RA. 2005. The loss of NKX3.1 expression in testicular-and prostate-cancers is not caused by promoter hypermethylation. Mol Cancer 4:8.
43. Lombardo F, Sgro P, Salacone P, Gilio B, Gandini L, Dondero F, Jannini EA, Lenzi A. 2005. Androgens and fertility. J Endocrinol Invest 28:51-55.
44. Lotan Y, Xu XC, Shaley M, Lotan R, Williams R, Wheeler TM, Thompson TC, Kadmon D. 2000. Differential expression of nuclear retinoid receptors in normal and malignant prostates. J Clin Oncol 18:116-121.
45. Mangelsdorf DJ, Evans RM. 1995. The RXR heterodimers and orphan receptors. Cell 83:841-850.
46. Mao GE, Reuter VE, Cordon-Cardo C, Dalbagni G, Scher HI, DeKernion JB, Zhang ZF, Rao J. 2004. Decreased retinoid X receptor-alpha protein expression in basal cells occurs in the early stage of human prostate cancer development. Cancer Epidemiol Biomarkers Prev 13:383-390.
47. Marshall H, Morrison A, Studer M, Popperl H, Krumlauf R. 1996. Retinoids and Hox genes. Faseb J 10:969-978.
48. Morrison A, Ariza-McNaughton L, Gould A, Featherstone M, Krumlauf R. 1997. HOXD4 and regulation of the group 4 paralog genes. Development 124:3135-3146.
49. Pasquali D, Thaller C, Eichele G. 1996. Abnormal level of retinoic acid in prostate cancer tissues. J Clin Endocrinol Metab 81:2186-2191.
50. Peehl DM, Wong ST, Stamey TA. 1993. Vitamin A regulates proliferation and differentiation of human prostatic epithelial cells. Prostate 23:69-78.
51. Pollard M, Luckert PH, Sporn MB. 1991. Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide. Cancer Res 51:3610-3611.
52. Prescott JL, Blok L, Tindall DJ. 1998. Isolation and androgen regulation of the human homeobox cDNA, NKX3.1. Prostate 35:71-80.
53. Reichman ME, Hayes RB, Ziegler RG, Schatzkin A, Taylor PR, Kahle LL, Fraumeni JF, Jr. 1990. Serum vitamin A and subsequent development of prostate cancer in the first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Cancer Res 50:2311-2315.
54. Ross SA, McCaffery PJ, Drager UC, De Luca LM. 2000. Retinoids in embryonal development. Physiol Rev 80:1021-1054.
55. Shen MM, Abate-Shen C. 2003. Roles of the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Dev Dyn 228:767-778.
56. Tanaka M, Komuro I, Inagaki H, Jenkins NA, Copeland NG, Izumo S. 2000. Nkx3.1, a murine homolog of Ddrosophila bagpipe, regulates epithelial ductal branching and proliferation of the prostate and palatine glands. Dev Dyn 219:248-260.
57. Trump DL, Smith DC, Stiff D, Adedoyin A, Day R, Bahnson RR, Hofacker J, Branch RA. 1997. A phase II trial of all-trans-retinoic acid in hormone-refractory prostate cancer: A clinical trial with detailed pharmacokinetic analysis. Cancer Chemother Pharmacol 39:349-356.
58. Vocke CD, Pozzatti RO, Bostwick DG, Florence CD, Jennings SB, Strup SE, Duray PH, Liotta LA, Emmert-Buck MR, Linehan WM. 1996. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res 56:2411-2416.
59. Yoon HG, Wong J. 2005. The corepressors SMRT and N-CoR are involved in agonist- and antagonist-regulated transcription by androgen receptor. Mol Endocrinol. 2005 Dec 22 [Epub ahead of print].
60. Zheng SL, Ju JH, Chang BL, Ortner E, Sun J, Isaacs SD, Wiley KE, Liu W, Zemedkun M, Walsh PC, Ferretti J, Gruschus J, Isaacs WB, Gelmann EP, Xu J. 2006. Germline mutation of NKX3.1 cosegregates with hereditary prostate cancer and alters the homeodomain structure and function. Cancer Res 66:69-77.
61. Zhong C, Yang S, Huang J, Cohen MB, Roy-Burman P. 2003. Aberration in the expression of the retinoid receptor, RXRalpha, in prostate cancer. Cancer Biol Ther 2:179-184.